健保藥品的HTA評估報告
- 1 芮寶喜凍晶注射劑 (Reblozyl)
- 2 吉舒達注射劑 (Keytruda Injection) HNSCC
- 3 吉舒達注射劑 (Keytruda Injection) NSCLC
- 4 Tecentriq injection, for intravenous use, 1200mg/20ml
- 5 維泰凱 (Vitrakvi)
- 6 Ofev
- 7 Blincyto for Injection
- 8 羅視萌注射劑 (Vabysmo solution for intravitreal injection)
- 9 杜避炎注射劑 (Dupixent) 氣喘
- 10 杜避炎注射劑 (Dupixent) AD及CRSwNP
- 11 Torsix® injection 10mg/mL 2mL 及5mL
- 12 百悅澤膠囊 (Brukinsa)
- 13 Uritos Tablets 0.1 mg
- 14 Lumicef Subcutaneous Injection 210 mg Syringe
- 15 修訂含SGLT-2 抑制劑與DPP-4 抑制劑複方製劑(如Steglujan、Glyxambi 及Qtern)藥品給付規定
- 16 祈萊亞靜脈輸注用懸浮液 (Kymriah® suspension for intravenous infusion)_ALL
- 17 祈萊亞靜脈輸注用懸浮液 (Kymriah® suspension for intravenous infusion)_DLBCL
- 18 Bavencio 20mg/mL Concentrate for Solution for Infusion
- 19 Tonvasca
- 20 Tremsolin Tablets 50mg、250mg